NORETHINDRONE ACETATE Drug Patent Profile

When do Norethindrone Acetate patents expire, and when can generic versions of Norethindrone Acetate launch?

Norethindrone Acetate is a drug marketed by Amneal Pharms, Aurobindo Pharma Ltd, Barr, Glenmark Pharms Ltd, Novast Labs, Xiromed, Barr Labs Inc, Dr Reddys Labs Sa, Apotex, and Barr Labs. and is included in twenty-nine NDAs.

The generic ingredient in NORETHINDRONE ACETATE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for NORETHINDRONE ACETATE

US Patents:	0
Applicants:	10
NDAs:	29
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	52
Patent Applications:	4,493
Drug Prices:	Drug price information for NORETHINDRONE ACETATE
DailyMed Link:	NORETHINDRONE ACETATE at DailyMed

See drug prices for NORETHINDRONE ACETATE

Recent Clinical Trials for NORETHINDRONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Geneva	NA
Cairo University	PHASE3
ViiV Healthcare	PHASE1

See all NORETHINDRONE ACETATE clinical trials

Pharmacology for NORETHINDRONE ACETATE

Drug Class

Progestin

US Patents and Regulatory Information for NORETHINDRONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xiromed	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	202742-001	Oct 30, 2014		DISCN	No	No
Xiromed	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	206120-001	Sep 12, 2017		DISCN	No	No
Amneal Pharms	NORETHINDRONE ACETATE	norethindrone acetate	TABLET;ORAL	200275-001	Jul 30, 2012	AB	RX	No	No

Market Dynamics and Financial Trajectory for Norethindrone Acetate

Last updated: February 12, 2026

---

What is the Market Size and Key Drivers for Norethindrone Acetate?

Norethindrone acetate (NAA) is a synthetic progestin used primarily in hormonal contraceptives, menopausal hormone therapy, and treatment of gynecological conditions. Its global market is driven by the increasing prevalence of reproductive health issues, expanding contraceptive use, and aging populations.

Market Size and Forecast:

• The global hormonal contraceptives market, of which NAA-based products form a segment, was valued at approximately $22.5 billion in 2021 and is projected to reach $29.8 billion by 2026, growing at a compound annual growth rate (CAGR) of roughly 5.8% [1].

• Norethindrone acetate represents about 30-40% of this segment, with annual sales estimated at around $4.5 billion in 2021. Projected growth indicates revenues could approach $6 billion by 2026.

Key Growth Drivers:

• Rising awareness and acceptance of hormonal contraceptives.

• Increasing adoption of menopause management therapies.

• Expanded approval and indications in emerging markets.

• The preference for oral and transdermal formulations that utilize NAA.

How Do Patent and Regulatory Landscapes Influence Market Dynamics?

Patent Status:

• The original patent protections for NAA formulations generally expired in major markets by the early 2010s, opening the market for generic manufacturers.

• Several generic versions now dominate production, resulting in downward pressure on prices but increased market penetration.

Regulatory Considerations:

• Regulatory approvals for new indications or formulations can extend market opportunities.

• The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other authorities have approved NAA for several indications, facilitating broader market access.

• Patent litigations or exclusivity extensions occasionally influence market exclusivity periods, impacting pricing strategies.

What Is the Competitive Landscape and Biodiversity of Norethindrone Acetate Products?

• Several global pharmaceutical companies, including Perrigo, Mylan, Ferring Pharmaceuticals, and Teva, manufacture NAA-based products.

• The market sees a mix of branded and generic products; generics constitute more than 70% of sales.

• Innovation primarily focuses on new delivery systems—transdermal patches, implants, or combined formulations with estrogen.

What Are the Financial Trends and Future Investment Opportunities?

• Despite the shift to generics, revenues remain substantial due to high demand and established manufacturing channels.

• R&D investments focus on optimizing formulations, delivery methods, and expanding indications, particularly for novel contraceptive devices and hormone therapy.

• Dependence on regulatory approvals and patent exclusivities presents risk, but market size and demand buffer against significant volatility.

What Are Potential Risks and Barriers?

• Regulatory challenges in different jurisdictions, especially regarding new indications.

• Patent litigations on newer formulations or delivery systems.

• Market saturation with generic products constraining profit margins.

• Shifts in consumer preferences towards non-hormonal or non-invasive alternatives.

---

Key Takeaways

• The Norethindrone acetate market is sizable, with global revenues estimated near $4.5 billion in 2021.

• Growth is driven by increasing contraceptive use, menopause management, and expanding markets in emerging economies.

• Patent expirations led to a proliferation of generics, sustaining revenues while pressuring prices.

• Market entry barriers include regulatory approvals, patent disputes, and competition from innovative delivery systems.

• R&D efforts focus on enhancing formulations and indications to sustain profitability.

---

FAQs

1. What are the main therapeutic uses of Norethindrone Acetate?
Primarily used in oral contraceptives, menopausal hormone therapy, and treatment of abnormal uterine bleeding.

2. How does patent expiration affect the NAA market?
Patent expirations facilitate generic manufacturing, increasing market competition and reducing prices but maintaining overall sales volume.

3. Which regions offer the highest growth potential for NAA products?
Emerging markets in Asia-Pacific, Latin America, and Africa show significant growth due to expanding healthcare infrastructure and contraceptive adoption.

4. Are there ongoing developments in NAA formulations?
Yes, research targets transdermal patches, long-acting implants, and combination therapies with estrogen.

5. What are the key risks associated with market expansion for NAA?
Regulatory delays, patent disputes, and shifts in consumer preferences toward non-hormonal options pose challenges.

---

Citations

[1] Grand View Research. Hormonal Contraceptives Market Size, Share & Trends Analysis Report (2022).